Trending
NFLX 
$186.35  $2.87 
AAPL 
$137.59  $0.24 
AMZN 
$2,151.82  $5.44 
TSLA 
$663.90  $45.52 
GOOG 
$2,186.26  $28.65 

NASDAQ:(LOGC) LOGICBIO is trending higher up more than 30%

NASDAQ:(LOGC) LOGICBIO is trending higher up more than 30%

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

Company initiates activities to resume dosing
Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022

LEXINGTON, Mass., May 9, 2022 /PRNewswire/ — LogicBioTherapeutics, Inc.(Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia. In its letter, the FDA acknowledged that the company satisfactorily addressed all clinical hold issues. The company has initiated activities to resume dosing as soon as possible.

Read the entire article here: https://www.prnewswire.com/news-releases/logicbio-therapeutics-announces-fda-lifts-clinical-hold-on-sunrise-trial-in-pediatric-patients-with-methylmalonic-acidemia-301542452.html

JOIN OUR NEWSLETTER

Signup today for free and be the first to get notified of breaking news.

Recent News

Follow Us

Add New Playlist